Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced that CEO Kimberly Blackwell will speak at the Wedbush PacGrow Healthcare Conference on August 10, 2022, at 10:20 a.m. ET. This panel will focus on targeted oncology strategies. The event will be accessible via a live webcast on the company's website, with an archived version available afterward. Zentalis specializes in small molecule therapeutics aimed at critical cancer pathways and has a diverse pipeline, including treatments like ZN-c3 and ZN-d5.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on August 1, 2022, that its Compensation Committee granted non-qualified stock options for 290,500 shares to new General Counsel Andrea Paul. This grant is part of the 2022 Employment Inducement Incentive Award Plan, aimed at attracting non-employee talent. The options have an exercise price of $28.82, equal to the stock's closing price on the grant date, a 10-year term, and will vest over four years contingent on continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Andrea Paul, J.D., as General Counsel and Corporate Secretary, effective August 1, 2022. With extensive experience in healthcare legal matters, Paul previously served in similar roles at LogicBio Therapeutics and Akebia Therapeutics. Dr. Kimberly Blackwell, CEO, expressed confidence in Paul's ability to navigate complex legal challenges, supporting the company's clinical ambitions. Zentalis focuses on developing small molecule therapeutics targeting cancer pathways and has a pipeline that includes product candidates for various cancer types.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation by CEO Kimberly Blackwell and CFO Melissa Epperly in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 a.m. ET. This event will be available via live webcast on the company’s website, with an archived version to follow. Zentalis is a clinical-stage biopharmaceutical company focusing on oncology therapeutics, developing candidates targeting pivotal cancer pathways, including ZN-c3 and ZN-d5. For more details, visit www.zentalis.com.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced the promotion of Cam Gallagher to President. Gallagher, a co-founder and former Executive Director, brings 30 years of experience in life sciences. He will lead corporate and business development initiatives under CEO Dr. Kimberly Blackwell's leadership. Gallagher expressed confidence in Zentalis' potential, especially regarding lead assets ZN-c3 and ZN-d5, as the company advances its clinical strategy. Zentalis focuses on developing small molecule therapeutics targeting biological pathways in cancer.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has successfully completed an underwritten offering of 10,330,000 shares at $19.38 per share, raising approximately $200.2 million. The proceeds will support ongoing and planned clinical trials for its innovative oncology candidates, including ZN-c3 and ZN-d5, as well as general corporate purposes. The offering was managed by prominent financial institutions including Morgan Stanley and Jefferies. This financing aims to bolster Zentalis's pipeline in the competitive oncology market.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of 10,330,000 shares of common stock at $19.38 per share, totaling approximately $200.2 million in gross proceeds. The offering is expected to close on May 18, 2022, subject to customary conditions. The net proceeds will fund ongoing and planned clinical trials, including ZN-c3 and ZN-d5, and for general corporate purposes. Zentalis aims to maintain sufficient funds for operations until the first quarter of 2025.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced leadership changes, appointing Kimberly Blackwell, MD, as the new CEO, succeeding Anthony Sun, MD, who will continue as CEO of joint venture Zentera Therapeutics. Blackwell, a board member with extensive oncology experience, will focus on accelerating the clinical development of lead candidates ZN-c3 and ZN-d5. Chairman Dave Johnson expressed confidence in the company’s potential, emphasizing their promising pipeline and cash runway.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced promising initial data on ZN-c3, a Wee1 inhibitor, from ongoing trials in advanced ovarian cancer and uterine serous carcinoma. The company received a $25 million equity investment from Pfizer to advance clinical development for ZN-c3 and ZN-d5. A Phase 1/2 study for ZN-d5 in relapsed AL amyloidosis has been initiated. As of March 31, 2022, Zentalis reported cash and marketable securities of $289.4 million, providing a cash runway into Q1 2024 after budget reallocations following the Pfizer investment.
Zentalis Pharmaceuticals has entered into a joint clinical development agreement with Pfizer for ZN-c3, a selective Wee1 inhibitor aimed at treating cancer. This partnership includes a $25 million investment from Pfizer through a share offering, expected to close on April 29, 2022. The funding extends Zentalis’ cash runway into Q1 2024, enabling continued clinical trials. Additionally, Pfizer's Adam Schayowitz will join Zentalis’ Scientific Advisory Board to enhance strategic clinical development. The company retains full ownership of its pipeline.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
